‹ Back to screener

AJANTPHARM.NS Ajanta Pharmaceuticals Ltd.

Healthcare

Price history

2025-08-21 ₹2656.50
2026-08-21 ₹3657.20
Change over window +37.67%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 52.5%
Trailing 20-day average 50.1%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 39913 20939 52.46%
2026-08-27 49671 30575 61.56%
2026-08-26 35227 19640 55.75%
2026-08-25 116770 69028 59.11%
2026-08-24 65679 35038 53.35%
2026-08-21 51825 24938 48.12%
2026-08-20 69455 25325 36.46%
2026-08-19 84540 24428 28.90%
2026-08-18 145440 73196 50.33%
2026-08-17 110437 57879 52.41%
2026-08-14 95494 49429 51.76%
2026-08-13 136792 55218 40.37%
2026-08-12 82946 45490 54.84%
2026-08-11 86524 41275 47.70%
2026-08-10 43409 21047 48.49%
2026-08-07 34852 19449 55.80%
2026-08-06 49287 25907 52.56%
2026-08-05 126648 58288 46.02%
2026-08-04 83877 42331 50.47%
2026-08-03 119278 65832 55.19%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers AJANTPHARM.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
13 Mar 2026 SHAILESH R SINGH Other Sell Market Sale 607 1881809 0.01% XBRL
29 Dec 2025 SHAILESH R SINGH Other Sell Market Sale 750 2034810 0.01% XBRL
13 Nov 2025 SHAILESH R SINGH Other Sell Market Sale 3000 7585290 0.01% XBRL
13 Nov 2025 SHAILESH R SINGH Other Sell Market Sale 2000 5130820 0.01% XBRL
26 Jun 2025 SHAILESH R SINGH Other Sell Market Sale 900 2316987 0.02% XBRL
28 Feb 2025 VANDANA SHAILESH SINGH Other Sell Market Sale 548 1491902 0.00% XBRL
31 Dec 2024 J K TRIPATHI Other Sell Market Sale 51 158100 0.00% XBRL
31 Dec 2024 J K TRIPATHI Other Sell Market Sale 49 149940 0.00% XBRL
31 Dec 2024 J K TRIPATHI Other Sell Market Sale 100 300000 0.00% XBRL
31 Dec 2024 J K TRIPATHI Other Sell Market Sale 100 289500 0.00% XBRL
31 Dec 2024 J K TRIPATHI Other Sell Market Sale 100 295000 0.00% XBRL
06 Sep 2024 ARVIND K AGRAWAL Other Buy ESOP 1000 2000 0.02% XBRL
06 Sep 2024 SEEMA AGRAWAL Immediate relative Sell Market Sale 5000 16436150 0.02% XBRL
06 Sep 2024 ARVIND K AGRAWAL Other Sell Market Sale 6000 19761720 0.01% XBRL
04 Sep 2024 J K TRIPATHI Other Sell Market Sale 200 561706 0.00% XBRL
04 Sep 2024 J K TRIPATHI Other Buy ESOP 500 1000 0.00% XBRL
04 Sep 2024 J K TRIPATHI Other Sell Market Sale 100 299103 0.00% XBRL
04 Sep 2024 J K TRIPATHI Other Sell Market Sale 100 320000 0.00% XBRL
16 Aug 2024 AAYUSH M AGRAWAL, TRUSTEE AAYUSH AGRAWAL TRUST Promoters Pledge Revokation of Pledge 17 53993 11.30% XBRL
16 Aug 2024 AAYUSH M AGRAWAL, TRUSTEE AAYUSH AGRAWAL TRUST Promoters Pledge Revokation of Pledge 169983 539883006 11.30% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers AJANTPHARM.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹3639.80 INR (live) · fetched 2026-08-23 21:33 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Ratios

P/E
43.21
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹3,639.80 / (₹10,560,000,000 / 125,350,000 shares) = ₹3,639.80 / ₹84.24 EPS
FY2025-26 · Annual filing
ROE
23.33%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹10,560,000,000 / ₹45,270,900,000 = 23.33%
FY2025-26 · Annual filing
Debt/Equity
0.05
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹2,119,900,000 / ₹45,270,900,000 = 0.05
FY2025-26 · Annual filing
Current Ratio
2.64
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹37,354,300,000 / ₹14,157,500,000 = 2.64
FY2025-26 · Annual filing
ROCE
29.41%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹13,937,600,000 / (₹45,270,900,000 + ₹2,119,900,000) = 29.41%
FY2025-26 · Annual filing
Dividend Yield
0.77%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹3,497,200,000 / 125,350,000 shares) / ₹3,639.80 = ₹27.90 / ₹3,639.80
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 13.4%
Net Profit (3y) N/A
Revenue (5y, 3.0y actual) 13.4%
Net Profit (5y) N/A
Revenue (10y, 3.0y actual) 13.4%
Net Profit (10y) N/A

Operating Margin Trend

Expanding

FY2022-23 20.1%
FY2023-24 26.6%
FY2024-25 26.0%
FY2025-26 25.6%

ROCE Trajectory

FY2022-23 22.2%
FY2023-24 31.4%
FY2024-25 31.9%
FY2025-26 29.4%

Earnings Quality

Net profit or operating cash flow was zero or negative in the base or latest year — a growth-rate comparison isn't defined across a sign change.

Sector-Relative Percentile (Healthcare)

ROE 93th
ROCE 96th
Debt/Equity 61th
P/E 59th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹1,054.08 Cr. ₹1,144.92 Cr. ₹1,186.64 Cr. ₹1,146.13 Cr. ₹1,170.41 Cr. ₹1,302.65 Cr. ₹1,353.73 Cr. ₹1,374.84 Cr. ₹1,421.64 Cr. ₹1,625.96 Cr. RevenueFromOperations
Net Profit ₹196.33 Cr. incl. minority ₹202.72 Cr. ₹238.43 Cr. incl. minority ₹245.77 Cr. ₹216.48 Cr. ₹232.88 Cr. ₹225.26 Cr. ₹255.34 Cr. ₹260.19 Cr. ₹273.77 Cr. ₹266.70 Cr. ₹329.96 Cr. incl. minority ₹334.22 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers AJANTPHARM.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent10560000000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital125350000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets37354300000.0
CurrentLiabilities14157500000.0
EquityAttributableToOwnersOfParent45270900000.0
BorrowingsCurrent + BorrowingsNoncurrent2119900000.0

My notes